<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: This meta-analysis aimed to compare the renal outcomes between <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> (ACEI)/<z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker (ARB) and other <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi> or placebo in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Publications were identified from Medline and Embase up to July 2011 </plain></SENT>
<SENT sid="2" pm="."><plain>Only randomised controlled trials comparing ACEI/ARB monotherapy with other active drugs or placebo were eligible </plain></SENT>
<SENT sid="3" pm="."><plain>The outcome of <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>, doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, microvascular complications, <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, macroalbuminuria and <z:mp ids='MP_0002871'>albuminuria</z:mp> regression were extracted </plain></SENT>
<SENT sid="4" pm="."><plain>Risk ratios were pooled using a random-effects model if <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> was present; a fixed-effects model was used in the absence of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Of 673 studies identified, 28 were eligible (n = 13-4,912) </plain></SENT>
<SENT sid="6" pm="."><plain>In direct meta-analysis, ACEI/ARB had significantly lower risk of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> doubling (pooled RR = 0.66 [95% CI 0.52, 0.83]), macroalbuminuria (pooled RR = 0.70 [95% CI 0.50, 1.00]) and <z:mp ids='MP_0002871'>albuminuria</z:mp> regression (pooled RR 1.16 [95% CI 1.00, 1.39]) than other <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi>, mainly <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi> (CCBs) </plain></SENT>
<SENT sid="7" pm="."><plain>Although the risks of <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> were lower in the ACEI/ARB group (pooled RR 0.82 [95% CI 0.64, 1.05] and 0.84 [95% CI 0.61, 1.15], respectively), the differences were not statistically significant </plain></SENT>
<SENT sid="8" pm="."><plain>The ACEI/ARB benefit over placebo was significant for <z:hpo ids='HP_0000001'>all</z:hpo> outcomes except <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>A network meta-analysis detected significant treatment effects across <z:hpo ids='HP_0000001'>all</z:hpo> outcomes for both active drugs and placebo comparisons </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our review suggests a consistent reno-protective effect of ACEI/ARB over other <z:chebi fb="0" ids="35674">antihypertensive drugs</z:chebi>, mainly CCBs, and placebo in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>The lack of any differences in BP decrease between ACEI/ARB and active comparators suggest this benefit is not due simply to the <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> effect </plain></SENT>
</text></document>